Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs McDonald's Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $282.56 (market cap $39.89B), while McDonald's Corp trades at $275 (market cap $195.10B). The key difference: McDonald's Corp is far larger — about 4.9× Alnylam Pharmaceuticals, Inc.'s market cap, and McDonald's Corp pays a 2.71% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MCD | |
|---|---|---|
Market Cap | $39.89B | $195.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $341.06 |
52-Week Low | $278.09 | $264.54 |
Enterprise Value | $38.15B | $248.82B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
McDonald's (MCD) trades at $274.60, down 0.68% on the day, with technical indicators showing a bearish trend while fundamentals remain solid. The company reported $26.89B revenue in 2025 with a 31.62% net margin, though Q3 2025 EPS missed expectations. Recent news highlights McDonald's new 'NEXT' growth strategy focusing on automation and menu innovation to counter competitive pressures and attract customers.
The stock presents a mixed outlook: strong cash flow and analyst consensus support upside to $325.50, but technical weakness and inflation risks pose near-term challenges. Investment appeal hinges on execution of strategic initiatives amid economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
